Balance Sheet

Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2017 - 2023)

Summit Therapeutics filings provide 6 years of Asset Writedowns and Impairment readings, the most recent being $474000.0 for Q1 2023.

Quarterly Asset Writedowns and Impairment changed N/A to $474000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $474000.0 through Dec 2023, down 94.4% year-over-year, with the annual reading at $474000.0 for FY2023, 94.4% down from the prior year.
Asset Writedowns and Impairment hit $474000.0 in Q1 2023 for Summit Therapeutics, down from $8.5 million in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $8.5 million in Q4 2022 and bottomed at -$852470.9 in Q1 2019.
Average Asset Writedowns and Impairment over 4 years is $2.2 million, with a median of $666500.0 recorded in 2020.